Recent Developments in Organometallic Supramolecular Complexes as Anticancer Drugs
Pp. 46-129 (84)
Cheng-He Zhou, Hui-Zhen Zhang, Sheng-Feng Cui, Jing-Song Lv, Cong-Yan Yan, Kun Wan, Yi-Yi Zhang, Shao-Lin Zhang, Gui-Xin Cai, Rong-Xia Geng and Guri L.V. Damu
The research and development of organometallic supramolecular complexes
as anticancer supramolecular drugs, which are aggregates mainly formed by one or
more inorganic metal compounds with one or more either inorganic or organic
molecules in general via coordination bonds, has been a quite rapidly developing,
increasingly active and newly rising highlight interdisciplinary field. Numerous efforts
have been directed toward organometallic supramolecular complexes as potential
anticancer agents and the unprecedented progress has been made. This has opened up a
wholly new and infinite space to create novel metal-based bioactive supermolecules.
More importantly, metal-based complex supermolecules as potential anticancer agents
with wide potential applications have become highlight topics in recent years, and are
becoming increasingly useful and important in preventing and treating cancer diseases.
In view of the rapid progress in organometallic complex anticancer supermolecules with
rich variation of structural types, this work systematically reviewed the recent research
and development of the whole range of metal-based supramolecular complexes as
anticancer agents mainly since 2009. The perspectives of the foreseeable future and
potential application of organometallic supramolecular complexes in cancer therapy
were also presented. It is hoped that this review will serve as a stimulant for new
thoughts in the quest for rational designs of more active and less toxic organometallic
supramolecular complex anticancer drugs.
Anticancer, cytotoxicity, metal complex, supramolecular drug,
platinum, palladium, copper, cobalt.
Laboratory of Bioorganic & Medicinal Chemistry, School of Chemistry and Chemical Engineering, Southwest University, Chongqing 400715, P.R. China